Why is Beryl Drugs falling/rising?

As of 18-Sep, Beryl Drugs Ltd is experiencing a price increase, currently at 23.57, reflecting a change of 0.57 or 2.48% upward. Today's price summary indicates that the stock has outperformed its sector by 1.43% and has shown a trend reversal after three consecutive days of decline. Despite a one-week return of -0.97%, the stock has performed positively over the past month with a return of +13.92%. However, it is important to note that the stock has a poor long-term performance, with a year-to-date return of -34.80% and a one-year return of -36.38%. The stock is trading at a discount compared to its peers, and while it has a very attractive valuation with a ROCE of 11, its profits have fallen by -37% over the past year, indicating underlying weaknesses.
In the broader market context, the stock's recent performance contrasts with the Sensex, which has shown a positive return of +1.80% over the past week and +2.14% over the past month. This indicates that while Beryl Drugs has seen a short-term uptick, it has underperformed the market significantly over the longer term, particularly with a one-year return that is much worse than the BSE500's -1.96%. The company's weak long-term fundamental strength, characterized by a low average ROCE of 7.27% and a poor EBIT to Interest ratio, suggests challenges in sustaining growth and servicing debt, which may contribute to investor caution despite the recent price increase.